Summary
Carcinoembryonic antigen (CEA), carbohydrate antigens 15–3, 19–9 and 72–4 (CA 15–3, CA 19–9 and CA 72–4), cytokeratin 19 fragments (CYFRA 21–1), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) were evaluated in pleural fluid for the diagnosis of malignant effusions. With a specificity of 99%, determined in a series of 121 benign effusions, the best individual diagnostic sensitivities in the whole series of 215 malignant effusions or in the subgroup of adenocarcinomas were observed with CEA, CA 15–3 and CA 72–4. As expected, a high sensitivity was obtained with SCC in squamous cell carcinomas and with NSE in small-cell lung carcinomas. CYFRA and/or CA 15–3 were frequently increased in mesotheliomas. Discriminant analysis showed that the optimal combination for diagnosis of non-lymphomatous malignant effusions was CEA + CA 15–3 + CYFRA + NSE: sensitivity of 94.4% with an overall specificity of 95%. In malignant effusions with a negative cytology, 83.9% were diagnosed using this association. The association CYFRA + NSE + SCC was able to discriminate adenocarcinomas from small-cell lung cancers. Regarding their sensitivity and their complementarity, CEA, CA 15–3, CYFRA 21–1, NSE and SCC appear to be very useful to improve the diagnosis of malignant pleural effusions.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asseo, PP & Tracopoulos, GD (1982). Simultaneous enzyme immunoassay of carcinoembryonic antigen in pleural effusion and serum. Am J Clin Pathol 77: 66–71.
Brown, GA, Ginsberg, PC & Harkaway, RC (1998). Prostatic adenocarcinoma diagnosed by prostate-specific antigen analysis of pleural fluid. Urol Int 60: 197–198.
Callet, N, Cohen-Solal Le Nir, CC, Berthelot, E & Pichon, MF (1998). Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations. Eur J Gynaecol Oncol 19: 50–56.
Cascinu, S, Del Ferro, E, Barbanti, I, Ligi, M, Fedeli, A & Catalano, G (1997). Tumor markers in the diagnosis of malignant serous effusions. Am J Clin Onco, l20: 247–250.
Daste, G, Serre, G, Mauduyt, M-A, Vincent, C, Caverivière, P & Soleilhavoup, JP (1991). Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions. Cytopathology 2: 19–28.
Doweck, I, Barak, M, Greenberg, E, Uri, N, Kellner, J, Lurie, M & Gruener, N (1995). Cyfra 21–1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 121: 177–181.
Fenton, KN & Richardson, JD (1995). Diagnosis and management of malignant pleural effusions. Am J Surg 170: 69–74.
Ferrer, JS, Munoz, XG, Orriols, RM, Light, RW & Morell, FB (1996). Evolution of idiopathic pleural effusion: a prospective, long-term follow-up study. Chest 109: 1508–1513.
Ferroni, P, Szpak, C, Greiner, JW, Simpson, JF, Guadagni, F, Johnston, WW & Colcher, D (1990). CA 72–4 radioimmunoassay in the diagnosis of malignant effusions. Comparison of various tumor markers. Int J Cancer 46: 445–451.
Garcia-Pachon, E, Padilla-Navas, I, Dosda, MD & Miralles-Llopis, A (1997). Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 111: 643–647.
Grem, J (1997). The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. Curr Opin Oncol 9: 380–387.
Guadagni, F, Roselli, M, Cosimelli, M, Ferroni, P, Spila, A, Cavaliere, F, Casaldi, V, Wappner, G, Abbolito, MR & Greiner, JW (1995). CA 72–4 serum marker – a new tool in the management of carcinoma patients. Cancer Invest 13: 227–238.
Hanley, JA & McNeil, BJ (1983). A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839–843.
Harris, RJ, Kavuru, MS, Rice, TW & Kirby, TJ (1995). The diagnostic and therapeutic utility of thoracoscopy. Chest 108: 828–841.
Hilgers, JH (1998). Natural antibodies against MUC1 protect against disease progression in early breast cancer. Tumor Biol 19: (S2)
Klockars, M, Lindgren, J, Pettersson, T, Hellstrom, PE & Norhagen, A (1980). Carcinoembryonic antigen in pleural effusions: a diagnostic and prognostic indicator. Eur J Cancer 16: 1149–1152.
Lembersky, BC & Thomas, LC (1996). Metastases of unknown primary site. Med Clin North Am 80: 153–171.
Leslie, WK & Kinasewitz, GT (1988). Clinical characteristics of the patient with nonspecific pleuritis. Chest 94: 603–608.
Loddenkemper, R & Boutin, C (1993). Thoracoscopy: present diagnostic and therapeutic indications. Eur Resp J 6: 1544–1555.
MacLean, GD, Reddish, MA & Longenecker, BM (1997). Prognostic significance of preimmunotherapy serum CA 27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J Immunother 20: 70–78.
Menard, O, Dousset, B, Jacob, C & Martinet, Y (1993). Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels. Eur J Cancer 29A: 1806–1809.
Mezger, J, Calavrezos, A, Drings, P, Gatzemeier, U, Kaukel, E, Konietzko, N, Koschel, G, Lamerz, R, Von Pawel, J & Romer, W (1994). Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant mesothelioma and carcinomatous pleural metastases. Lung 172: 183–184.
Morita, T, Kikuchi, T, Hashimoto, S, Kobayashi, Y & Tokue, A (1997). Cytokeratin-19 fragment (CYFRA 21–1) in bladder cancer. Eur Urol 32: 237–244.
Niklinski, J & Furman, M (1995). Clinical tumour markers in lung cancer. Eur J Cancer Prev 4: 129–138.
Nyberg, P, Soderblom, T, Pettersson, T, Riska, H, Klockars, M & Linko, L (1996). Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis. Thorax 51: 92–94.
Paone, G, De Angelis, G, Greco, S, Fiorucci, F, Bisetti, A & Ameglio, F (1996). Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis. J Cancer Res Clin Oncol 122: 499–503.
Peto, J, Hodgson, JT, Matthews, FE & Jones, JR (1995). Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535–539.
Plebani, M, Basso, D, Navaglia, F, De Paoli, M, Tommasini, A & Cipriani, A (1995). Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer 72: 170–173.
Pujol, JL, Grenier, J, Daures, JP, Daver, A, Pujol, H & Michel, FB (1993). Serum fragment of cytokeratin subunit 19 measured by CYFRA 21–1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61–66.
Rapellino, M, Pecchio, F, Piantino, P & Cellerino, A (1990). Tumor markers determination in extrahematic fluids. J Nucl Med Allied Sci 34: 128–136.
Rittgers, RA, Loewenstein, MS, Feinerman, AE, Kupchik, HZ, Marcel, BR, Koff, RS & Zamcheck, N (1978). Carcinoembryonic antigen levels in benign and malignant pleural effusions. Ann Intern Med 88: 631–634.
Romero, S, Fernandez, C, Arriero, JM, Espasa, A, Candela, A, Martin, C & Sanchez-Paya, J (1996). CEA, CA 15–3 and CYFRA 21–1 in serum and pleural fluid of patients with pleural effusions. Eur Respir, J9: 17–23.
Sahn, SA (1988). The pleura. Am Rev Respir Dis 138: 184–234.
Salama, G, Miédougé, M, Rouzaud, P, Mauduyt, M-A, Pujazon, M-C, Vincent, C, Carles, P & Serre, G (1998). Evaluation of pleural CYFRA 21–1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 77: 472–476.
Satoh, H, Sumi, M, Yagyu, H, Ishikawa, H, Suyama, T, Naitoh, T, Saitoh, T & Hasegawa, S (1995). Clinical evaluation of CYFRA 21–1 in malignant pleural fluids. Oncology 52: 211–214.
Serre, G, Daste, G, Vincent, C, Mauduyt, M-A & Soleilhavoup, JP (1990). Diagnostic approach to the patient with pleural effusion: cytologic analysis of pleural fluid. In: International Trends in General Thoracic Surgery Vol 6, Deslauriers J, Lacquet LK (eds) CV Mosby: St Louis, pp. 35–45.
Shimokata, K, Niwa, Y, Yamamoto, M, Sasou, H & Morishita, M (1989). Pleural fluid neuron-specific enolase. A useful diagnostic marker for small cell lung cancer pleuritis. Chest 95: 602–603.
Soletormos, G, Nielsen, D, Schioler, V, Skovsgaard, T & Dombernowsky, P (1996). Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 42: 564–575.
Toumbis, M, Rasidakis, A, Passalidou, E, Kalomenidis, J, Alchanatis, M, Orphanidou, D & Jordanoglou, J (1996). Evaluation of CYFRA 21–1 in malignant and benign pleural effusions. Anticancer Res 16: 2101–2104.
Villena, V, Lopez-Encuentra, A, Echave-Sustaeta, J, Martin-Escribano, P, Ortuno-de-Solo, B & Estenoz-Alfaro, J (1996). Diagnostic value of CA 72–4, carcinoembryonic antigen, CA 15–3, and CA 19–9 assay in pleural fluid. A study of 207 patients. Cancer 78: 736–740.
Villena, V, Lopez Encuentra, A & Rodriguez, FP (1998). False-positive results of carcinoembryonic antigen in pleural effusions. Chest 113: 1143–1144.
Zeimet, AG, Marth, C, Offner, FA, Obrist, P, Uhl-Steidl, M, Feichtinger, H, Stadlmann, S, Daxenbichler, G & Dapunt, O (1996). Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 62: 384–389.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Miédougé, M., Rouzaud, P., Salama, G. et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 81, 1059–1065 (1999). https://doi.org/10.1038/sj.bjc.6690807
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690807
Keywords
This article is cited by
-
Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis
BMC Cancer (2017)
-
Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array
Diagnostic Pathology (2015)
-
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
Medical Oncology (2013)
-
Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions
Clinical & Experimental Metastasis (2012)
-
Evaluation of pleural fluid survivin and XIAP for the diagnosis of malignant pleural effusion
Tumor Biology (2012)